De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Invitae Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Invitae's earnings have been declining at an average annual rate of -53.3%, while the Healthcare industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 26.5% per year.
Belangrijke informatie
-53.3%
Groei van de winst
-34.1%
Groei van de winst per aandeel
Healthcare Groei van de industrie | 8.5% |
Inkomstengroei | 26.5% |
Rendement op eigen vermogen | n/a |
Nettomarge | -299.1% |
Laatste winstupdate | 30 Sep 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely
Dec 20Invitae: Revenue Troubles Build
Aug 09Invitae Is Treading In Competitive Waters
Jul 16Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares
Jun 26Invitae: What Happened At The JP Morgan Health Conference
Jan 19Invitae guides Q4 revenue above estimates
Jan 09Invitae Likely Hasn't Reached The Bottom Yet
Dec 15Invitae: This Turnaround Could Be Painful
Nov 15Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M
Nov 08Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved
Sep 22Why Invitae Corporation Could Underperform
Aug 17Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines
Aug 09Opbrengsten en kosten
Hoe Invitae geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 23 | 482 | -1,441 | 361 | 256 |
30 Jun 23 | 494 | -800 | 371 | 285 |
31 Mar 23 | 510 | -3,117 | 389 | 336 |
31 Dec 22 | 516 | -3,106 | 411 | 402 |
30 Sep 22 | 520 | -3,212 | 436 | 462 |
30 Jun 22 | 501 | -3,109 | 484 | 473 |
31 Mar 22 | 481 | -451 | 462 | 464 |
31 Dec 21 | 460 | -379 | 474 | 416 |
30 Sep 21 | 435 | -408 | 599 | 405 |
30 Jun 21 | 389 | -313 | 522 | 345 |
31 Mar 21 | 319 | -613 | 496 | 284 |
31 Dec 20 | 280 | -602 | 438 | 241 |
30 Sep 20 | 245 | -445 | 254 | 171 |
30 Jun 20 | 233 | -421 | 243 | 180 |
31 Mar 20 | 241 | -303 | 230 | 160 |
31 Dec 19 | 217 | -242 | 201 | 142 |
30 Sep 19 | 196 | -195 | 176 | 107 |
30 Jun 19 | 177 | -148 | 151 | 76 |
31 Mar 19 | 161 | -131 | 130 | 66 |
31 Dec 18 | 148 | -129 | 126 | 63 |
30 Sep 18 | 128 | -140 | 119 | 61 |
30 Jun 18 | 109 | -136 | 115 | 56 |
31 Mar 18 | 86 | -133 | 104 | 52 |
31 Dec 17 | 68 | -123 | 91 | 46 |
30 Sep 17 | 52 | -108 | 77 | 45 |
30 Jun 17 | 40 | -105 | 65 | 45 |
31 Mar 17 | 31 | -102 | 57 | 44 |
31 Dec 16 | 25 | -100 | 52 | 45 |
30 Sep 16 | 19 | -100 | 48 | 44 |
30 Jun 16 | 15 | -97 | 45 | 44 |
31 Mar 16 | 11 | -97 | 43 | 45 |
31 Dec 15 | 8 | -90 | 39 | 43 |
30 Sep 15 | 6 | -81 | 35 | 38 |
30 Jun 15 | 4 | -71 | 31 | 32 |
31 Mar 15 | 3 | -57 | 26 | 26 |
31 Dec 14 | 2 | -47 | 21 | 22 |
30 Sep 14 | 1 | -40 | 16 | 21 |
30 Jun 14 | 1 | -35 | 13 | 20 |
31 Mar 14 | 0 | -29 | 10 | 18 |
31 Dec 13 | 0 | -25 | 8 | 16 |
Kwaliteitswinsten: NVTA.Q is currently unprofitable.
Groeiende winstmarge: NVTA.Q is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NVTA.Q is unprofitable, and losses have increased over the past 5 years at a rate of 53.3% per year.
Versnelling van de groei: Unable to compare NVTA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: NVTA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6%).
Rendement op eigen vermogen
Hoge ROE: NVTA.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.